

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 incubation period, physical activity and COVID-19 risk, long COVID in children and adolescents, Paxlovid studies

Peer reviewed journals featured:

- Systematic reviews on:
 - Incubation period of COVID-19 caused by unique SARS-CoV-2 strains [here](#)
 - Physical activity and risk of infection, severity, and mortality of COVID-19 [here](#)
 - Prediction models for diagnosis and prognosis of COVID-19 (update) [here](#)
 - The effect of influenza vaccine in reducing the severity of COVID-19 outcomes [here](#)
- A randomised controlled trial of bamlanivimab for COVID-19 outpatients [here](#)
- Observational studies on:
 - Clinical features and burden of long COVID-19 in children and adolescents [here](#)
 - Severity and clinical spectrum of COVID-19 in NSW children during 2021 [here](#)
 - Oral nirmatrelvir and ritonavir (Paxlovid) in non-hospitalised vaccinated COVID-19 patients [here](#)
 - Nirmatrelvir use and severe COVID-19 outcomes during the Omicron surge [here](#)
 - Risk of preterm birth, small for gestational age at birth, and stillbirth after COVID-19 vaccination during pregnancy [here](#)
 - Risk for myocardial infarction, stroke, and pulmonary embolism after COVID-19 vaccines in adults under 75 years of age in France [here](#)
 - Awareness of Omicron infection in adults with recent COVID-19 seropositivity [here](#)
 - Clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory COVID-19 patients [here](#)
 - SARS-CoV-2 antibody response in children infected with pre-Omicron variants [here](#)
 - Window of SARS-CoV-2 infectiousness & temporal correlation with symptom onset [here](#)
 - Neurological and psychiatric risk trajectories after SARS-CoV-2 infection [here](#) and associated commentary [here](#)
 - COVID-19 vaccine effectiveness against Omicron variant infection and hospitalisation in patients taking immunosuppressive medications [here](#) and associated commentary [here](#)
 - Myocarditis after COVID-19 mRNA vaccination in Australia [here](#)
 - Natural immunity to SARS-CoV-2 and breakthrough infections in cancer patients [here](#)
 - Antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2 [here](#)
 - Comparing 2021 English COVID-19 roadmap projections with public health data [here](#)
 - Medium-term SARS-CoV-2 transmission dynamics in England in the Omicron era [here](#)

- Commentary on:
 - Emergency preparedness during the public health emergency [here](#)
 - COVID-19 vaccines in children under 5 years of age [here](#)

Letters and correspondence discussed:

- SARS-CoV-2 infection rate in asymptomatic healthcare workers in Sweden [here](#)
- Validation of clinical risk models for predicting COVID-19 severity [here](#)
- Long-term effectiveness with Comirnaty (Pfizer) vaccine among adolescents in South Korea [here](#)
- The correlation between body mass index and COVID-19 transmission risk [here](#)
- Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated US state [here](#)

Guidance and reports

- The World Health Organization published:
 - Its weekly epidemiological report on COVID-19 [here](#)
 - A good practice statement on the use of second booster doses [here](#)
- The Therapeutic Goods Administration (TGA):
 - Released information about provisional determinations for COVID-19 treatments [here](#)
 - Granted provisional determination for sabizabulin for COVID-19 treatment [here](#)

News and blogs

- Results from India's 12 molnupiravir clinical trials remain unpublished [here](#)
- Increased risk of some neurological and psychiatric disorders remains two years after infection [here](#)
- Could tiny blood clots cause long COVID's puzzling symptoms? [here](#)
- A guide on COVID-19 boosters [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).